The Effect of Colesevelam on the Microbiome in Postoperative Crohn’s Disease

This small pilot study demonstrated that patients who were given colesevelam, were more likely to be in disease remission at their 6-12 months colonoscopy review compared with those not treated. Furthermore, treatment with colesevelam may have a role in altering the microbiome to help maintain remission states in postoperative Crohn's disease. Larger mechanistic studies are now needed to confirm these findings and demonstrate statistical significance as well as investigate whether this benefit may be present even in those patients with 75SeHCAT negative disease.

Authors

Institutions

Publication Details

Journal
Inflammatory Bowel Diseases
Published
2024-10-18
DOI
https://doi.org/10.1093/ibd/izae230
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Effect of Colesevelam on the Microbiome in Postoperative Crohn’s Disease

Adam D. Farmer, Mohammed Nabil Quraishi, Helen Steed, Andrew D. Beggs et al.
Inflammatory Bowel Diseases
Inflammatory Bowel Disease
article

The Effect of Colesevelam on the Microbiome in Postoperative Crohn’s Disease

Adam D. Farmer, Mohammed Nabil Quraishi, Helen Steed, Andrew D. Beggs, Esther M. John, Jeffrey Butterworth, Hafid O. Al‐Hassi, Aditi Kumar, Manushri Jain, Jonathan Segal, Matthew Brookes, Mohammed E. El‐Asrag
article en

Abstract

This small pilot study demonstrated that patients who were given colesevelam, were more likely to be in disease remission at their 6-12 months colonoscopy review compared with those not treated. Furthermore, treatment with colesevelam may have a role in altering the microbiome to help maintain remission states in postoperative Crohn's disease. Larger mechanistic studies are now needed to confirm these findings and demonstrate statistical significance as well as investigate whether this benefit may be present even in those patients with 75SeHCAT negative disease.

Inflammatory Bowel DiseasesVol. 31(2)
University of Wolverhampton (GB), University Hospitals Birmingham NHS Foundation Trust (GB), The Royal Melbourne Hospital (AU), The University of Melbourne (AU), Aston University (GB), Manchester Academic Health Science Centre (GB), Salford Royal NHS Foundation Trust (GB), Saint Louis University Hospital (US), University of Manchester (GB), Aston Medical (France) (FR), Shrewsbury and Telford Hospital NHS Trust (GB), The Royal Wolverhampton NHS Trust (GB), Health & Life (Taiwan) (TW), University of Birmingham (GB)
Bowel and Cancer Research
Good health and well-being
Openalex Percentile: Top 80%
Inflammatory Bowel Disease
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.